ROLE OF PROBIOTICS IN THE ERADICATION OF H.PYLORI
DOI:
https://doi.org/10.36557/2674-9432.2026v5n4p190-207Abstract
The gut microbiota is composed of microorganisms essential to gastrointestinal health, while probiotics are live microorganisms that help balance the microbiota and strengthen the intestinal barrier. H. pylori causes chronic inflammation in the stomach, leading to gastritis and peptic ulcers; the use of probiotics may help reduce inflammation and improve the treatment of H. pylori. This study aims to evaluate the effectiveness of probiotics in eradicating H. pylori and their impact on the gut microbiota. The methodology involved an integrative literature review to assess the role of probiotics in eradicating H. pylori. Scientific articles published between 2020 and 2025, in Portuguese and English, were searched in the PUBMED, MEDLINE, and LILACS databases. After selection, 6 articles were analyzed and summarized in a table with identification, title, authors, year, type of study, and results. The results revealed that six studies evaluating the use of probiotics in the treatment of H. pylori infection showed promising results. These microorganisms reduced gastrointestinal symptoms and adverse effects of treatment, improved the diversity of the gut microbiota, and increased the H. pylori eradication rate in some cases. Furthermore, they reduced inflammation and improved the response to treatment. The probiotics studied included Saccharomyces boulardii, Bacillus clausii, Lactobacillus reuteri, Bifidobacterium, Bacteroides, and Lactobacillus. Supplementation with probiotics improved H. pylori eradication and reduced adverse effects of antibiotic therapy. Probiotics increased the eradication rate (79.4% vs. 71.1%) and reduced adverse gastrointestinal events (23.6% vs. 37.7%). They also modulated the oral microbiota and reduced inflammation. Effective strains included Lactobacillus reuteri, L. casei, L. rhamnosus GG, and Saccharomyces boulardii. The results suggest that probiotics are promising adjuvants in the treatment of H. pylori, but more studies are needed. It is concluded that probiotics are promising adjuvants in the treatment of H. pylori, reducing adverse gastrointestinal effects and improving tolerance to antibiotic therapy. Strains such as Lactobacillus reuteri, L. casei, and Saccharomyces boulardii are effective. Although there is heterogeneity in the studies, probiotics are a safe and effective alternative to complement conventional therapy.
The gut microbiota is composed of microorganisms essential to gastrointestinal health, while probiotics are live microorganisms that help balance the microbiota and strengthen the intestinal barrier. H. pylori causes chronic inflammation in the stomach, leading to gastritis and peptic ulcers; the use of probiotics may help reduce inflammation and improve the treatment of H. pylori. This study aims to evaluate the effectiveness of probiotics in eradicating H. pylori and their impact on the gut microbiota. The methodology involved an integrative literature review to assess the role of probiotics in eradicating H. pylori. Scientific articles published between 2020 and 2025, in Portuguese and English, were searched in the PUBMED, MEDLINE, and LILACS databases. After selection, 6 articles were analyzed and summarized in a table with identification, title, authors, year, type of study, and results. The results revealed that six studies evaluating the use of probiotics in the treatment of H. pylori infection showed promising results. These microorganisms reduced gastrointestinal symptoms and adverse effects of treatment, improved the diversity of the gut microbiota, and increased the H. pylori eradication rate in some cases. Furthermore, they reduced inflammation and improved the response to treatment. The probiotics studied included Saccharomyces boulardii, Bacillus clausii, Lactobacillus reuteri, Bifidobacterium, Bacteroides, and Lactobacillus. Supplementation with probiotics improved H. pylori eradication and reduced adverse effects of antibiotic therapy. Probiotics increased the eradication rate (79.4% vs. 71.1%) and reduced adverse gastrointestinal events (23.6% vs. 37.7%). They also modulated the oral microbiota and reduced inflammation. Effective strains included Lactobacillus reuteri, L. casei, L. rhamnosus GG, and Saccharomyces boulardii. The results suggest that probiotics are promising adjuvants in the treatment of H. pylori, but more studies are needed. It is concluded that probiotics are promising adjuvants in the treatment of H. pylori, reducing adverse gastrointestinal effects and improving tolerance to antibiotic therapy. Strains such as Lactobacillus reuteri, L. casei, and Saccharomyces boulardii are effective. Although there is heterogeneity in the studies, probiotics are a safe and effective alternative to complement conventional therapy.
Downloads
References
MANNA, O. M.; CARUSO BAVISOTTO, C.; GRATIE, M. I.; DAMIANI, P.; BONAVENTURA, G.; CAPPELLO, F.; TOMASELLO, G.; D’ANDREA, V. Targeting Helicobacter pylori Through the “Muco-Microbiotic Layer” Lens: The Challenge of Probiotics and Microbiota Nanovesicles. Nutrients, v. 17, n. 569, p. 1-13, 2025. Disponível em: https://doi.org/10.3390/nu17030569.
Bai, X., Zhu, M., He, Y., Wang, T., Tian, D., & Shu, J. (2022). Os impactos dos probióticos na terapia de erradicação do Helicobacter pylori. Arquivos de Microbiologia, 204, 692. https://doi.org/10.1007/s00203-022-03314-w
ELE, X.; XIE, Y.; ZHU, Y.; ZHUANG, K.; HUO, L.; YU, Y.; GUO, Q.; SHU, X.; XIONG, Z.; ZHANG, Z.; LYU, B.; LU, N. Probióticos modulam a microbiota gastrointestinal após a erradicação do Helicobacter pylori: um ensaio clínico multicêntrico, randomizado, duplo-cego e controlado por placebo. Fronteiras em Imunologia, v. 13, p. 1033063, 2022. DOI: 10.3389/fimmu.2022.1033063.
NABAVI-RAD, A.; SADEGHI, A.; ASADZADEH AGHDAEI, H.; YADEGAR, A.; SMITH, S. M.; ZALI, M. R. A espada de dois gumes da suplementação probiótica na estrutura da microbiota intestinal no tratamento do Helicobacter pylori. Gut Microbes, v. 14, n. 1, p. 2108655, 2022. DOI: 10.1080/19490976.2022.2108655.
MESTRE, A.; SATHIYA NARAYANAN, R.; RIVAS, D.; JOHN, J.; ABDULQADER, M. A.; KHANNA, T.; CHANDRA CHAKINALA, R.; GUPTA, S. O papel dos probióticos na gestão da infecção por Helicobacter pylori. Cureus, v. 14, n. 6, p. e26463, 2022. DOI: 10.7759/cureus.26463.
BAI, X.-F.; TIAN, D.; WANG, T.-Y.; SHU, J.-C.; HE, Y.-J.; ZHU, M.-J. The impact of probiotics on gut microbiota in the eradication of Helicobacter pylori infection: a systematic review. European Review for Medical and Pharmacological Sciences, v. 27, p. 6736-6743, 2023.
IVASHKIN, Vladimir; MAEV, Igor; POLUEKTOVA, Elena; et al. Eficácia e segurança do postbiótico contido Lactobacillus reuteri DSM 17648 como terapia adjuvante na erradicação de Helicobacter pylori em adultos com dispepsia funcional: um estudo randomizado, duplo-cego, controlado por placebo. *Clinical and Translational Gastroenterology*, v. 15, e00750, 2024. Disponível em: https://doi.org/10.14309/ctg.0000000000000750.
KEIKHA, Masoud; KARBALEAI, Mohsen. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterology, v. 21, p. 388, 2021. Disponível em: https://doi.org/10.1186/s12876-021-01977-1.
HE, C.; KONG, F.; CHAI, X.; ZOU, C.; ZHU, X.; ZHAO, D. Effect of Probiotic-Assisted Eradication of cagA+/vacAs1m1 Helicobacter pylori on Intestinal Flora. BioMed Research International, v. 2022, p. 1-10, 2022. Disponível em: https://doi.org/10.1155/2022/8607671.
CÁRDENAS, P. A. et al. Efeito de Saccharomyces boulardii CNCM I-745 como tratamento complementar da infecção por Helicobacter pylori na microbiota intestinal. European Journal of Clinical Microbiology & Infectious Diseases, 2020. Disponível em: https://doi.org/10.1007/s10096-020-03854-3.
PLOMER, Manuel; PEREZ III, Marcos; GREIFENBERG, Dorothea Maren. Efeito das cápsulas de Bacillus clausii na redução dos efeitos adversos associados à terapia de erradicação de Helicobacter pylori: um ensaio clínico randomizado, duplo-cego e controlado. Infect Dis Ther, 2020. Disponível em: https://doi.org/10.1007/s40121-020-00333-2.
VARGAS-JIMÉNEZ, José; CAMPOS-NÚÑEZ, Christian. Tratamiento de primera línea para erradicación de Helicobacter pylori: todavía una terapia eficaz. Acta Médica Costarricense, v. 65, n. 1, p. 21-25, jan.-mar. 2023.
RECINOS AGUIRRE, Alejandra Maria; GARCÍA PALOMO, Rodrigo Fernando. Terapias associadas a probióticos na erradicação de Helicobacter pylori. Revista Científica de Ciências Médicas, v. 26, n. 1, p. 59-66, 2023.
Velasco, Bernardita; Durán, Cynthia; Bahamondez-Canas, Tania F. - Nuevas perspectivas para el tratamiento de la infección por Helicobacter pylori - New perspectives in the treatment of Helicobacter pylori infection - ARS med. (Santiago, En línea);46(3): 60-69, ago. 20, 2021.
JARAMILLO-TRUJILLO, Gilberto; OTERO-REGINO, William Alberto; ESTRADA-OROZCO, Kelly Patricia. Eficácia e segurança dos probióticos como adjuvantes na erradicação do Helicobacter pylori. Revisão sistemática e meta-análise. rev.fac.med. , Bogotá , v. 71, n. 2, e11, junho de 2023.
Gil Llanes, Ileana; Barroso Márquez, Lisset; Rodríguez Martínez, Oxalis; Chao González, Lissette; Samada Suárez, Marcia; Tusen Toledo, Yunia; Martínez Leyva, Ludmila. - Leche fermentada simbiótica y triple terapia en el tratamiento de Helicobacter pylori - Rev. cuba. med. mil;51(1)mar. 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Isadora Furlaneto Freire , Nathalia Karoline Nunes Ribeiro Machado Lemes, Letícia Timóteo Murta, Amanda Lemes Quirino, Isabella Mesquita Peixoto, Júlia Martins da Silva, Bianca Machado Crisóstomo, Gustavo Caetano Sousa Lagares, Iza Mickele Silva Rocha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Você tem o direito de:
- Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
- Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
- O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.
De acordo com os termos seguintes:
- Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
